[en] [en] BACKGROUND: Because our center participated in the first-in-human trial with Perceval (LivaNova, Sallugia, Italy) in 2007, this series represents the longest available clinical follow-up (11 years) with sutureless technology in aortic valve replacement.
METHODS: We collected all clinical and echocardiographic follow-up in 468 consecutive patients who received Perceval at our institution between 2007 and 2017. In 57% of cases, surgery was combined with coronary artery bypass grafting (39%), mitral valve surgery (17%), or other procedures (13%).
RESULTS: Mean age was 79 years, mean EuroSCORE II was 5.1 ± 5.5 (range, 0.8-67) and mean Society of Thoracic Surgeons score was 5.8 ± 5.5. Mean cross-clamp times for isolated and combined procedures were 39 and 79 minutes, respectively. Observed all-cause 30-day mortality was 3.2%, with an early stroke rate of 1.8%. Pacemaker implantation rate was 7.9% overall, but only 3.9% in patients without preexisting conduction or rhythm disorders. All-cause mortality at 1 and 2 years was 8.8% ± 1.3% and 13.2% ± 1.6%, respectively. At the latest echocardiographic follow-up (mean, 3 years; range, 1-11 years), peak and mean gradients were 23 ± 10 mm Hg and 13 ± 6 mm Hg, respectively. During follow-up, we explanted 5 valves for endocarditis, and none for structural valve degeneration.
CONCLUSIONS: After more than 11 years of continued clinical use of the Perceval sutureless valve, we observe low mortality and stroke rates, with good hemodynamic behavior of the valve. None of our patients was reoperated for structural valve degeneration. Because of the key benefits of this rapid-deployment valve, it has an added value in surgical aortic valve replacement.
Disciplines :
Surgery
Author, co-author :
Szecel, Delphine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chirurgie cardio-vasculaire et thoracique ; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
Eurlings, Roxanne; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
Rega, Filip; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
Verbrugghe, Peter; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
Meuris, Bart; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. Electronic address: bart.meuris@uzleuven.be
Shrestha, M., Fischlein, T., Meuris, B., et al. European multicentre experience with the sutureless Perceval valve: clinical and haemodynamic outcomes up to 5 years in over 700 patients. Eur J Cardiothorac Surg 49 (2016), 234–241.
Flameng, W., Herregods, M.C., Hermans, H., et al. Effect of sutureless implantation of the Perceval S aortic valve bioprosthesis on intraoperative and early postoperative outcomes. J Thorac Cardiovasc Surg 142 (2011), 1453–1457.
Meuris, B., Flameng, W.J., Laborde, F., Folliguet, T.A., Haverich, A., Shrestha, M., Five-year results of the pilot trial of a sutureless valve. J Thorac Cardiovasc Surg 150 (2015), 84–88.
Gersak, B., Fischlein, T., Folliguet, T.A., et al. Sutureless, rapid deployment valves and stented bioprosthesis in aortic valve replacement: recommendations of an International Expert Consensus Panel. Eur J Cardiothorac Surg 49 (2016), 709–718.
Glauber, M., Moten, S., MD, Quaini, E., et al. International expert consensus on sutureless and rapid deployment valves in aortic valve replacement using minimally invasive approaches. Innovations 11 (2016), 165–173.
Van Brabandt, H., Neyt, M., Hulstaert, F., Transcatheter aortic valve implantation (TAVI): risky and costly. BMJ, 31, 2012, 345.
Neyt, M., Van Brabandt, H., Devriese, S., Van De Sande, S., A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population. BMJ Open, 4, 2012, 2.
Dvir, D., Bourguignon, T., Otto, C.M., et al. Standardized definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves. Circulation 137 (2018), 388–399.
Capodanno, D., Petronio, A.S., Prendergast, B., et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 38 (2017), 3382–3390.
Salaun, E., Mahjoub, H., Girerd, N., et al. Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement. Circulation 138 (2018), 971–985.
Thourani, V.H., Forcillo, J., Szeto, W.Y., et al. Outcomes in 937 intermediate-risk patients undergoing surgical aortic valve replacement in PARTNER-2A. Ann Thorac Surg 105 (2018), 1322–1329.
Reardon, M.J., Van Mieghem, N.M., Popma, J.J., et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376 (2017), 1321–1331.
Brennan, J.M., Thomas, L., Cohen, D.J., et al. Transcatheter versus surgical aortic valve replacement: propensity-matched comparison. J Am Coll Cardiol 70 (2017), 439–450.
Meco, M., Montisci, A., Miceli, A., et al. Sutureless Perceval aortic valve versus conventional stented bioprostheses: meta-analysis of postoperative and midterm results in isolated aortic valve replacement. J Am Heart Assoc 7 (2018), 1–9.
Cerillo, A.G., Amoretti, F., Mariani, M., et al. Increased gradients after aortic valve replacement with the perceval valve: the role of oversizing. Ann Thorac Surg 106 (2018), 121–128.
Meuris, B., Michiel, M., Verstraete, L., et al. Oversizing in sutureless aortic heart valves leads to higher gradients and increased pacemaker rates. Circulation, 140, 2019, A12791.
Meuris, B., De Praetere, H., Strasly, M., et al. A novel tissue treatment to reduce mineralization of bovine pericardial heart valves. J Thorac Cardiovasc Surg 156 (2018), 197–206.
